Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 88

1.

The safety and immunogenicity of two novel live attenuated monovalent (serotype 2) oral poliovirus vaccines in healthy adults: a double-blind, single-centre phase 1 study.

Van Damme P, De Coster I, Bandyopadhyay AS, Revets H, Withanage K, De Smedt P, Suykens L, Oberste MS, Weldon WC, Costa-Clemens SA, Clemens R, Modlin J, Weiner AJ, Macadam AJ, Andino R, Kew OM, Konopka-Anstadt JL, Burns CC, Konz J, Wahid R, Gast C.

Lancet. 2019 Jul 13;394(10193):148-158. doi: 10.1016/S0140-6736(19)31279-6. Epub 2019 Jun 4.

2.

Dynamics of Evolution of Poliovirus Neutralizing Antigenic Sites and Other Capsid Functional Domains during a Large and Prolonged Outbreak.

Shaw J, Jorba J, Zhao K, Iber J, Chen Q, Adu F, Adeniji A, Bukbuk D, Baba M, Henderson E, Dybdahl-Sissoko N, McDonald S, Weldon WC, Gumede N, Oberste MS, Kew OM, Burns CC.

J Virol. 2018 Apr 13;92(9). pii: e01949-17. doi: 10.1128/JVI.01949-17. Print 2018 May 1.

3.

Are Circulating Type 2 Vaccine-derived Polioviruses (VDPVs) Genetically Distinguishable from Immunodeficiency-associated VDPVs?

Zhao K, Jorba J, Shaw J, Iber J, Chen Q, Bullard K, Kew OM, Burns CC.

Comput Struct Biotechnol J. 2017 Oct 12;15:456-462. doi: 10.1016/j.csbj.2017.09.004. eCollection 2017.

4.

Prolonged Excretion of Poliovirus among Individuals with Primary Immunodeficiency Disorder: An Analysis of the World Health Organization Registry.

Macklin G, Liao Y, Takane M, Dooling K, Gilmour S, Mach O, Kew OM, Sutter RW; iVDPV Working Group.

Front Immunol. 2017 Sep 25;8:1103. doi: 10.3389/fimmu.2017.01103. eCollection 2017.

5.

The Global Polio Laboratory Network as a Platform for the Viral Vaccine-Preventable and Emerging Diseases Laboratory Networks.

Diop OM, Kew OM, de Gourville EM, Pallansch MA.

J Infect Dis. 2017 Jul 1;216(suppl_1):S299-S307. doi: 10.1093/infdis/jix092.

6.

Fifty Years of Global Immunization at CDC, 1966-2015.

Mast EE, Cochi SL, Kew OM, Cairns KL, Bloland PB, Martin R.

Public Health Rep. 2017 Jan/Feb;132(1):18-26. doi: 10.1177/0033354916681490. Epub 2016 Dec 19. No abstract available.

7.

Preventing Vaccine-Derived Poliovirus Emergence during the Polio Endgame.

Pons-Salort M, Burns CC, Lyons H, Blake IM, Jafari H, Oberste MS, Kew OM, Grassly NC.

PLoS Pathog. 2016 Jul 6;12(7):e1005728. doi: 10.1371/journal.ppat.1005728. eCollection 2016 Jul.

8.

Molecular Properties of Poliovirus Isolates: Nucleotide Sequence Analysis, Typing by PCR and Real-Time RT-PCR.

Burns CC, Kilpatrick DR, Iber JC, Chen Q, Kew OM.

Methods Mol Biol. 2016;1387:177-212. doi: 10.1007/978-1-4939-3292-4_9.

PMID:
26983735
9.

Renaissance of an "old" vaccine.

Sutter RW, Kew OM.

Lancet Infect Dis. 2016 Mar;16(3):268-70. doi: 10.1016/S1473-3099(15)00526-5. Epub 2015 Dec 21. No abstract available.

PMID:
26719059
10.

Update on Vaccine-Derived Polioviruses - Worldwide, January 2014-March 2015.

Diop OM, Burns CC, Sutter RW, Wassilak SG, Kew OM; Centers for Disease Control and Prevention (CDC).

MMWR Morb Mortal Wkly Rep. 2015 Jun 19;64(23):640-6.

11.

Possible eradication of wild poliovirus type 3--worldwide, 2012.

Kew OM, Cochi SL, Jafari HS, Wassilak SG, Mast EE, Diop OM, Tangermann RH, Armstrong GL; Centers for Disease Control and Prevention (CDC).

MMWR Morb Mortal Wkly Rep. 2014 Nov 14;63(45):1031-3.

12.

Polio-free certification and lessons learned--South-East Asia region, March 2014.

Bahl S, Kumar R, Menabde N, Thapa A, McFarland J, Swezy V, Tangermann RH, Jafari HS, Elsner L, Wassilak SG, Kew OM, Cochi SL.

MMWR Morb Mortal Wkly Rep. 2014 Oct 24;63(42):941-6.

13.

Development of an efficient entire-capsid-coding-region amplification method for direct detection of poliovirus from stool extracts.

Arita M, Kilpatrick DR, Nakamura T, Burns CC, Bukbuk D, Oderinde SB, Oberste MS, Kew OM, Pallansch MA, Shimizu H.

J Clin Microbiol. 2015 Jan;53(1):73-8. doi: 10.1128/JCM.02384-14. Epub 2014 Oct 22.

14.

Vaccine-derived polioviruses.

Burns CC, Diop OM, Sutter RW, Kew OM.

J Infect Dis. 2014 Nov 1;210 Suppl 1:S283-93. doi: 10.1093/infdis/jiu295. Review.

PMID:
25316847
15.

Update on vaccine-derived polioviruses - worldwide, July 2012-December 2013.

Diop OM, Burns CC, Wassilak SG, Kew OM; Centers for Disease Control and Prevention (CDC).

MMWR Morb Mortal Wkly Rep. 2014 Mar 21;63(11):242-8.

16.

The 2010 outbreak of poliomyelitis in Tajikistan: epidemiology and lessons learnt.

Yakovenko ML, Gmyl AP, Ivanova OE, Eremeeva TP, Ivanov AP, Prostova MA, Baykova OY, Isaeva OV, Lipskaya GY, Shakaryan AK, Kew OM, Deshpande JM, Agol VI.

Euro Surveill. 2014 Feb 20;19(7):20706.

17.

Identification of vaccine-derived polioviruses using dual-stage real-time RT-PCR.

Kilpatrick DR, Ching K, Iber J, Chen Q, Yang SJ, De L, Williams AJ, Mandelbaum M, Sun H, Oberste MS, Kew OM.

J Virol Methods. 2014 Mar;197:25-8. doi: 10.1016/j.jviromet.2013.11.017. Epub 2013 Dec 7.

PMID:
24321704
18.

Complete genome sequence of the last representative genotype of wild indigenous poliovirus type 1, which circulated in Brazil.

Tavares FN, da Costa EV, Kew OM, da Silva EE.

Genome Announc. 2013 Oct 31;1(6). pii: e00811-13. doi: 10.1128/genomeA.00811-13.

19.

Oral poliovirus vaccine evolution and insights relevant to modeling the risks of circulating vaccine-derived polioviruses (cVDPVs).

Duintjer Tebbens RJ, Pallansch MA, Kim JH, Burns CC, Kew OM, Oberste MS, Diop OM, Wassilak SG, Cochi SL, Thompson KM.

Risk Anal. 2013 Apr;33(4):680-702. doi: 10.1111/risa.12022. Epub 2013 Mar 7.

PMID:
23470192
20.

Paralytic poliomyelitis associated with Sabin monovalent and bivalent oral polio vaccines in Hungary.

Estívariz CF, Molnár Z, Venczel L, Kapusinszky B, Zingeser JA, Lipskaya GY, Kew OM, Berencsi G, Csohán A.

Am J Epidemiol. 2011 Aug 1;174(3):316-25. doi: 10.1093/aje/kwr070. Epub 2011 Jun 17.

PMID:
21685412
21.

Poliovirus vaccines: past, present, and future.

Nathanson N, Kew OM.

Arch Pediatr Adolesc Med. 2011 Jun;165(6):489-91. doi: 10.1001/archpediatrics.2011.77. No abstract available.

PMID:
21646582
22.

From emergence to eradication: the epidemiology of poliomyelitis deconstructed.

Nathanson N, Kew OM.

Am J Epidemiol. 2010 Dec 1;172(11):1213-29. doi: 10.1093/aje/kwq320. Epub 2010 Oct 26. Review.

23.

Rapid group-, serotype-, and vaccine strain-specific identification of poliovirus isolates by real-time reverse transcription-PCR using degenerate primers and probes containing deoxyinosine residues.

Kilpatrick DR, Yang CF, Ching K, Vincent A, Iber J, Campagnoli R, Mandelbaum M, De L, Yang SJ, Nix A, Kew OM.

J Clin Microbiol. 2009 Jun;47(6):1939-41. doi: 10.1128/JCM.00702-09. Epub 2009 Apr 22.

24.

Transmission of imported vaccine-derived poliovirus in an undervaccinated community in Minnesota.

Alexander JP, Ehresmann K, Seward J, Wax G, Harriman K, Fuller S, Cebelinski EA, Chen Q, Jorba J, Kew OM, Pallansch MA, Oberste MS, Schleiss M, Davis JP, Warshawsky B, Squires S, Hull HF; Vaccine-Derived Poliovirus Investigations Group.

J Infect Dis. 2009 Feb 1;199(3):391-7. doi: 10.1086/596052.

PMID:
19090774
25.

Estimating the extent of vaccine-derived poliovirus infection.

Wringe A, Fine PE, Sutter RW, Kew OM.

PLoS One. 2008;3(10):e3433. doi: 10.1371/journal.pone.0003433. Epub 2008 Oct 29.

26.

Uncertainty and sensitivity analyses of a decision analytic model for posteradication polio risk management.

Duintjer Tebbens RJ, Pallansch MA, Kew OM, Sutter RW, Bruce Aylward R, Watkins M, Gary H, Alexander J, Jafari H, Cochi SL, Thompson KM.

Risk Anal. 2008 Aug;28(4):855-76. doi: 10.1111/j.1539-6924.2008.01078.x. Epub 2008 Jul 4.

PMID:
18627544
27.

The risks, costs, and benefits of possible future global policies for managing polioviruses.

Thompson KM, Tebbens RJ, Pallansch MA, Kew OM, Sutter RW, Aylward RB, Watkins M, Gary HE Jr, Alexander J, Jafari H, Cochi SL.

Am J Public Health. 2008 Jul;98(7):1322-30. doi: 10.2105/AJPH.2007.122192. Epub 2008 May 29.

28.

Molecular epidemiology of wild poliovirus type 1 circulation in West and Central Africa, from 1997 to 1999, using genotyping with a restriction fragment length polymorphism assay.

Gouandjika-Vasilache I, Burns CC, Gumede N, Guillot S, Ménard D, Dosseh A, Akoua-Koffi C, Pallansch MA, Kew OM, Delpeyroux F.

Arch Virol. 2008;153(3):409-16. Epub 2007 Dec 4.

PMID:
18060590
29.

Vaccine-associated paralytic poliomyelitis in a patient with MHC class II deficiency.

Parvaneh N, Shahmahmoudi S, Tabatabai H, Zahraei M, Mousavi T, Esteghamati AR, Gooya MM, Mamishi S, Nategh R, Kew OM.

J Clin Virol. 2007 Jun;39(2):145-8. Epub 2007 May 16.

PMID:
17509935
30.

Development and consideration of global policies for managing the future risks of poliovirus outbreaks: insights and lessons learned through modeling.

Thompson KM, Duintjer Tebbens RJ, Pallansch MA, Kew OM, Sutter RW, Aylward RB, Watkins M, Gary H, Alexander JP, Venczel L, Johnson D, Cáceres VM, Sangrujee N, Jafari H, Cochi SL.

Risk Anal. 2006 Dec;26(6):1571-80.

PMID:
17184398
31.

Risks of paralytic disease due to wild or vaccine-derived poliovirus after eradication.

Tebbens RJ, Pallansch MA, Kew OM, Cáceres VM, Jafari H, Cochi SL, Sutter RW, Aylward RB, Thompson KM.

Risk Anal. 2006 Dec;26(6):1471-505.

PMID:
17184393
32.

Poliovirus vaccine shedding among persons with HIV in Abidjan, Cote d'Ivoire.

Hennessey KA, Lago H, Diomande F, Akoua-Koffi C, Caceres VM, Pallansch MA, Kew OM, Nolan M, Zuber PL.

J Infect Dis. 2005 Dec 15;192(12):2124-8. Epub 2005 Nov 8.

PMID:
16288377
33.

Vaccine-derived polioviruses and the endgame strategy for global polio eradication.

Kew OM, Sutter RW, de Gourville EM, Dowdle WR, Pallansch MA.

Annu Rev Microbiol. 2005;59:587-635. Review.

PMID:
16153180
34.

A dynamic model of poliomyelitis outbreaks: learning from the past to help inform the future.

Duintjer Tebbens RJ, Pallansch MA, Kew OM, Cáceres VM, Sutter RW, Thompson KM.

Am J Epidemiol. 2005 Aug 15;162(4):358-72. Epub 2005 Jul 13. Review.

PMID:
16014773
35.

Environmental surveillance of wild poliovirus circulation in Egypt--balancing between detection sensitivity and workload.

Hovi T, Blomqvist S, Nasr E, Burns CC, Sarjakoski T, Ahmed N, Savolainen C, Roivainen M, Stenvik M, Laine P, Barakat I, Wahdan MH, Kamel FA, Asghar H, Pallansch MA, Kew OM, Gary HE Jr, deGourville EM, El Bassioni L.

J Virol Methods. 2005 Jun;126(1-2):127-34.

PMID:
15847928
36.

Vaccine policy changes and epidemiology of poliomyelitis in the United States.

Alexander LN, Seward JF, Santibanez TA, Pallansch MA, Kew OM, Prevots DR, Strebel PM, Cono J, Wharton M, Orenstein WA, Sutter RW.

JAMA. 2004 Oct 13;292(14):1696-701.

PMID:
15479934
37.

Multiplex PCR method for identifying recombinant vaccine-related polioviruses.

Kilpatrick DR, Ching K, Iber J, Campagnoli R, Freeman CJ, Mishrik N, Liu HM, Pallansch MA, Kew OM.

J Clin Microbiol. 2004 Sep;42(9):4313-5.

38.

Circulating vaccine-derived polioviruses: current state of knowledge.

Kew OM, Wright PF, Agol VI, Delpeyroux F, Shimizu H, Nathanson N, Pallansch MA.

Bull World Health Organ. 2004 Jan;82(1):16-23. Epub 2004 Feb 26. Review.

39.

Search for poliovirus carriers among people with primary immune deficiency diseases in the United States, Mexico, Brazil, and the United Kingdom.

Halsey NA, Pinto J, Espinosa-Rosales F, Faure-Fontenla MA, da Silva E, Khan AJ, Webster AD, Minor P, Dunn G, Asturias E, Hussain H, Pallansch MA, Kew OM, Winkelstein J, Sutter R; Polio Project Team.

Bull World Health Organ. 2004 Jan;82(1):3-8.

40.

Retrospective analysis of a local cessation of vaccination against poliomyelitis: a possible scenario for the future.

Korotkova EA, Park R, Cherkasova EA, Lipskaya GY, Chumakov KM, Feldman EV, Kew OM, Agol VI.

J Virol. 2003 Dec;77(23):12460-5.

41.

Prolonged detection of indigenous wild polioviruses in sewage from communities in Egypt.

El Bassioni L, Barakat I, Nasr E, de Gourville EM, Hovi T, Blomqvist S, Burns C, Stenvik M, Gary H, Kew OM, Pallansch MA, Wahdan MH.

Am J Epidemiol. 2003 Oct 15;158(8):807-15.

PMID:
14561671
42.

Serial recombination during circulation of type 1 wild-vaccine recombinant polioviruses in China.

Liu HM, Zheng DP, Zhang LB, Oberste MS, Kew OM, Pallansch MA.

J Virol. 2003 Oct;77(20):10994-1005.

43.

Polio eradication: the OPV paradox.

Dowdle WR, De Gourville E, Kew OM, Pallansch MA, Wood DJ.

Rev Med Virol. 2003 Sep-Oct;13(5):277-91. Review.

PMID:
12931339
44.

Molecular evolution of a type 1 wild-vaccine poliovirus recombinant during widespread circulation in China.

Liu HM, Zheng DP, Zhang LB, Oberste MS, Pallansch MA, Kew OM.

J Virol. 2000 Dec;74(23):11153-61.

45.

Molecular and antigenic characterization of a highly evolved derivative of the type 2 oral poliovaccine strain isolated from sewage in Israel.

Shulman LM, Manor Y, Handsher R, Delpeyroux F, McDonough MJ, Halmut T, Silberstein I, Alfandari J, Quay J, Fisher T, Robinov J, Kew OM, Crainic R, Mendelson E.

J Clin Microbiol. 2000 Oct;38(10):3729-34.

46.

Intratypic differentiation & partial nucleotide sequencing of poliovirus isolates of northern India.

Dhole TN, Kapoor A, Agarwal J, Isomura S, Kew OM.

Indian J Med Res. 2000 May;111:151-6.

PMID:
10943066
47.

Evolution of circulating wild poliovirus and of vaccine-derived poliovirus in an immunodeficient patient: a unifying model.

Gavrilin GV, Cherkasova EA, Lipskaya GY, Kew OM, Agol VI.

J Virol. 2000 Aug;74(16):7381-90.

48.

Resolution of the pathways of poliovirus type 1 transmission during an outbreak.

Shulman LM, Handsher R, Yang CF, Yang SJ, Manor J, Vonsover A, Grossman Z, Pallansch M, Mendelson E, Kew OM.

J Clin Microbiol. 2000 Mar;38(3):945-52.

49.

Prolonged replication of a type 1 vaccine-derived poliovirus in an immunodeficient patient.

Kew OM, Sutter RW, Nottay BK, McDonough MJ, Prevots DR, Quick L, Pallansch MA.

J Clin Microbiol. 1998 Oct;36(10):2893-9.

50.

Outbreak of poliomyelitis in Gizan, Saudi Arabia: cocirculation of wild type 1 polioviruses from three separate origins.

Afif H, Sutter RW, Kew OM, Fontaine RE, Pallansch MA, Goyal MK, Cochi SL.

J Infect Dis. 1997 Feb;175 Suppl 1:S71-5.

PMID:
9203695

Supplemental Content

Support Center